Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Markart, T. Luboeinski, R. Schmidt, M. Wygrecka, P. Mahavadi, M. Korfei, K. Mayer, W. Seeger, A. Guenther, C. Ruppert (Giessen, Germany). Elevated alveolar antioxidant levels in chronic fibrosing interstitial lung diseases. Eur Respir J 2008; 32: Suppl. 52, 4221

Member's Comments

No comment yet.

Related content which might interest you: Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Increased CCL18 production in interstitial lung diseases is associated with fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 38s Year: 2004 Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD) Source: Eur Respir J 2007; 30: Suppl. 51, 110s Year: 2007 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 KL-6 as a potential therapeutic biomarker in fibrosing interstitial lung diseases Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Increased BALF eosinophils and underlying interstitial lung disease Source: Eur Respir J 2005; 26: Suppl. 49, 541s Year: 2005 Physiological study of small airway function in fibrosing interstitial lung disease Source: Eur Respir J 2007; 30: Suppl. 51, 578s Year: 2007 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Elevated levels of adenosine in the lungs lead to chronic lung injury and pulmonary hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Pertechnegas lung clearance in different forms of interstitial lung disease Source: Eur Respir J 2002; 19: 31-36 Year: 2002 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015